EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Neurocrine Biosciences Inc. (N1BI34) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Neurocrine Biosciences Inc. BRL 40.76, price BRL 37.36, upside +9.1%, quality 70 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · BR · Home US

NB Some data Sep 29, 2026

Neurocrine Biosciences Inc.

N1BI34 · SA

NeutralThe stock looks roughly fairly valued with average quality.

·Fair value R$40.76 · Fairly valued (+9.1%)
✓Quality 70/100
✓Healthy Growth (revenue 5y +22.3 %/yr)
✓Highly profitable · 21.6% net margin (TTM)
✓Low debt · generates free cash flow
✓Ranks above peers (10/10)
✓Wide moat 77/100
!Insider activity 40/100
!Evidence only medium, so the estimate is less certain
Watch Neurocrine Biosciences Inc. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

R$45.78 R$19.58 Fair Value R$40.76 Oct 2020 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 29, 2026.

How to read this chart

60‑month range R$19.58 – R$45.78 · fair‑value band R$25.86 – R$52.99 · the R$37.36 price screens below the R$40.76 fair value. Dashed = 300-day average. As of Sep 29, 2026.

Follow Neurocrine Biosciences in your weekly email

Every Wednesday you see whether Neurocrine Biosciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.

Show more

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Stock analysis

Neurocrine Biosciences Inc. (N1BI34) currently trades at R$37.36, while our model-based Fair Value estimate is R$40.76, so the stock looks roughly fairly valued today (gap 8.3%).

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of R$55.76 per share, and 12 of the 24 models we run sit above the R$37.36 price.

Bear case: the Asset-Based group reads lowest at R$5.66, and 12 of the 24 models stay below the price. Evidence for this calculation is medium.

Scenario range: R$25.86 (bear) to R$52.99 (bull), the price of R$37.36 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 70/100 (solid quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Neurocrine Biosciences Inc. reported revenue of $2.9B in FY2025 versus $1.1B in FY2021, a compound +26.0%/yr. Reported net income was $479M in FY2025, compounding +52.0%/yr from FY2021.

Key figures

Market cap R$90.6B (≈ $17.3B) · P/E ratio 22.2 · P/S ratio 3.72 · EPS (TTM) R$1.68 · Net margin 16.7% · Return on equity 22.5% · Return on assets (EBIT) 10.8% · Operating margin 22.8%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).

What moves the price

The share trades about 18% below its 52-week high and 18% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at 9%, N1BI34 screens cheaper than that median.

Fair Value models

Bear R$25.86 Fair Value R$40.76 Bull R$52.99
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (R$1.27 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF R$39.56 R$61.18 R$130.04 75
EPV R$15.63 R$17.93 R$19.94 74
Growth DCF R$37.31 R$67.82 R$129.47 74
All 24 models by family
DCF Models
FCF DCF R$39.56 R$61.18 R$130.04 75
Owner Earnings R$25.68 R$56.08 R$119.89 71
5Y Revenue Exit R$24.01 R$37.95 R$66.94 70
5Y EBITDA Exit R$25.46 R$40.88 R$71.01 73
5Y P/E Exit R$27.66 R$55.76 R$93.42 68
10Y Revenue Exit R$28.26 R$54.59 R$69.68 67
10Y EBITDA Exit R$29.98 R$57.70 R$103.85 65
10Y P/E Exit R$31.58 R$62.44 R$111.68 61
Earnings-Based
Graham-Dodd R$8.45 R$58.94 R$82.71 63
Lynch FV R$22.05 R$31.49 R$40.94 61
PEG = 1.0 R$22.05 R$31.49 R$40.94 57
EPV R$15.63 R$17.93 R$19.94 74
Multiples
P/E Multiple R$20.51 R$27.34 R$34.18 63
P/S Multiple R$15.85 R$21.13 R$26.41 58
P/B Multiple R$15.85 R$21.13 R$26.41 55
EV/EBIT R$22.35 R$29.18 R$36.02 66
EV/EBITDA R$19.44 R$25.30 R$31.17 67
EV/Revenue R$16.48 R$22.75 R$29.02 54
Asset-Based
NCAV (Graham) R$4.22 R$5.66 R$8.45 54
Growth DCF
Growth DCF R$37.31 R$67.82 R$129.47 74
Rev-Margin DCF R$24.10 R$43.19 R$78.94 69
Economic Profit
Residual Income R$8.39 R$10.99 R$17.11 69
ROIC Compounder R$19.99 R$29.58 R$38.32 71
Growth Earnings
Growth-Adj P/E R$28.73 R$41.05 R$53.36 67

Open the full fair value analysis →

Notify me when N1BI34 reaches fair value

Put N1BI34 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 70/100

Of which business quality 72 · Market factors (momentum, volatility) 53

Profitability 67
Margins and returns on capital today
Quality Growth 55
Are margins and returns improving?
Cashflow 92
Earnings quality: real cash, not paper profit
Fin. Strength 90
Balance sheet, leverage, solvency risk
Investment 33
Disciplined investing over empire-building
Low Volatility 81
Calm price path (market factor)
Momentum 43
Price trend over the last 3–12 months (market factor)
52W Momentum 37
Distance to the 52-week high (market factor)
Net Issuance 72
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+21.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+24.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.3%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+30.2%
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+39.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year+39.2%
Dividend (yield on the price)0.0%
Profit margin 2018 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.8% → 22%
2025 sits 89% above its own trend. The rate follows the median trend of the last 5 years, not that single year.

Watch N1BI34, get fair value alerts →

Earlier news

News mood ⓘNews mood, the average tone of recent news (100 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Positive
Recent news coverage is more positive than average.

Compare Neurocrine Biosciences Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 600 stocks

Beats the industry median on 9/9 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 70 · Top 25%
Fair Value upside +52.0% · Top 25%
Profitability
Return on equity (TTM) 22.5% · Top 25%
Return on assets 11.6% · Top 25%
Net margin (TTM) 21.6% · Top 25%
Operating margin (TTM) 22.8% · Top 25%
Growth and dividend
Revenue growth 42.2% · Top 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (TTM) 22.2× · Cheaper than median
PEG 0.49× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)99 · sector 17
FUTURE (revenue growth)100 · sector 24
PAST (return on equity)90 · sector 27
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 30

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Merck KGaA MRK €134.45 €108.94 −19%
Takeda Pharmaceutical Company TAK $18.90 $11.45 −39%
Teva Pharmaceutical Industries Limited TEVA $39.31 $20.88 −47%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,852 ₹1,979 +7%
Galderma Group GALD CHF 163.00 CHF 110.32 −32%
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥44.86 ¥49.35 +10%
Haleon plc HLN $9.26 $8.49 −8%
Sandoz Group SDZ CHF 71.16 CHF 40.32 −43%
Zoetis Inc ZTS $70.30 $110.50 +57%
Divi's Laboratories Limited DIVISLAB ₹9,620 ₹1,871 −81%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Neurocrine Biosciences Inc. · Fair Value
R$40.76 +8%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Neurocrine Biosciences Inc. Fair Value". https://www.fairvalue-calculator.com/stock/N1BI34

Frequently asked questions

Is Neurocrine Biosciences Inc. (N1BI34) overvalued or undervalued?
As of Sep 29, 2026, our model estimates a fair value of R$40.76 versus a price of R$37.36, about +9% upside (fairly valued).
What is the fair value of N1BI34?
Our model-based fair value for Neurocrine Biosciences Inc. is R$40.76 (as of Sep 29, 2026), built from audited fundamentals. The current price: R$37.36.
What is the quality score of N1BI34?
Neurocrine Biosciences Inc. has a Quality Score of 70/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Neurocrine Biosciences Inc. (N1BI34)?
Our model-based price target is the fair value of R$40.76 (as of Sep 29, 2026) from 24 valuation models. Cautious scenario R$25.86, optimistic scenario R$52.99. It is a calculation from audited fundamentals, not an analyst target.
What is the Neurocrine Biosciences Inc. stock forecast for 2026?
Our models put fair value at R$40.76, about +9% upside versus a price of R$37.36 (fairly valued). Cautious scenario R$25.86, optimistic scenario R$52.99. The calculation is refreshed regularly with new filings.
What is the revenue of Neurocrine Biosciences Inc. (N1BI34)?
Neurocrine Biosciences Inc. reported trailing-twelve-month revenue of about $3.1B (latest available figure, as of Sep 29, 2026).
What is the intrinsic value of Neurocrine Biosciences Inc. (N1BI34)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Neurocrine Biosciences Inc. it is R$40.76 per share (as of Sep 29, 2026), against a price of R$37.36. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Neurocrine Biosciences Inc. stock overvalued or undervalued in 2026?
As of Sep 29, 2026, N1BI34 trades below its calculated fair value: price R$37.36, fair value R$40.76, a gap of about +9% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of N1BI34?
No. The price is what the market pays today (R$37.36); the fair value is what the company's own numbers justify (R$40.76). For Neurocrine Biosciences Inc. the two are R$3.40 per share apart. That gap is exactly why we show both numbers side by side.
How much is Neurocrine Biosciences Inc. worth?
The market values Neurocrine Biosciences Inc. at about R$90.6B (market capitalisation, as of Sep 29, 2026). Per share that is R$37.36; our models calculate a fair value of R$40.76 per share.
What do the bullish and bearish scenarios say about N1BI34?
Our models span a range for Neurocrine Biosciences Inc.: cautious scenario R$25.86, base R$40.76, optimistic R$52.99 per share (as of Sep 29, 2026, price R$37.36). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of N1BI34?
Neurocrine Biosciences Inc. trades at a price-to-earnings ratio of 22.2 (as of Sep 29, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of R$40.76 is built from several models across several years. Other multiples: PEG 0.5.
What is the PEG ratio of N1BI34?
The PEG ratio of Neurocrine Biosciences Inc. is 0.49 (P/E divided by earnings growth, as of Sep 29, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Neurocrine Biosciences Inc. (N1BI34)?
Balance-sheet figures for Neurocrine Biosciences Inc. (as of Sep 29, 2026): return on equity 22.5%. They feed the Quality Score of 70/100, which measures business quality independently of the share price.
How far is N1BI34 from its 52-week high?
Neurocrine Biosciences Inc. trades at R$37.36, about 18% below its 52-week high of R$45.78 and 18% above the low of R$31.62 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of R$40.76 is for.
Which stocks are comparable to Neurocrine Biosciences Inc.?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Neurocrine Biosciences Inc. stock attractive at the current price?
The data as of Sep 29, 2026: price R$37.36, calculated fair value R$40.76 (+9%), Quality Score 70/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of N1BI34 calculated?
We run Neurocrine Biosciences Inc. through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of R$40.76, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Neurocrine Biosciences Inc. currently trades 8 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Neurocrine Biosciences Inc. (N1BI34)?
The closing price on Oct 2, 2026 was R$37.36. Our model-based fair value is R$40.76, about +9% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Neurocrine Biosciences Inc. right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (R$25.86 to R$52.99) leaves room in how you read the outcome.

Key figures of Neurocrine Biosciences Inc.

How large is the market capitalisation of Neurocrine Biosciences Inc. (N1BI34)?
The market capitalisation of Neurocrine Biosciences Inc. is R$90.6B (≈ $17.3B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Neurocrine Biosciences Inc. (N1BI34)?
The price-to-sales ratio of Neurocrine Biosciences Inc. is 3.72 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Neurocrine Biosciences Inc. (N1BI34)?
Earnings per share at Neurocrine Biosciences Inc. are R$1.68 (price ÷ EPS = P/E 22.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Neurocrine Biosciences Inc. (N1BI34)?
The net margin of Neurocrine Biosciences Inc. is 16.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Neurocrine Biosciences Inc. (N1BI34)?
The return on equity (ROE) of Neurocrine Biosciences Inc. is 22.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Neurocrine Biosciences Inc. (N1BI34)?
On an EBIT basis the return on assets of Neurocrine Biosciences Inc. is 10.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Neurocrine Biosciences Inc. (N1BI34)?
The operating margin of Neurocrine Biosciences Inc. is 22.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Neurocrine Biosciences Inc. (N1BI34)?
Revenue at Neurocrine Biosciences Inc. is growing +42.2% versus a year earlier (3y avg +24.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Neurocrine Biosciences Inc. (N1BI34)?
Earnings per share at Neurocrine Biosciences Inc. are growing +23.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Neurocrine Biosciences Inc. (N1BI34) generate?
The free cash flow of Neurocrine Biosciences Inc. is $749M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Neurocrine Biosciences Inc. (N1BI34) carry?
The net debt of Neurocrine Biosciences Inc. is $335M (fiscal year 2021, ≈ 0.4 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Neurocrine Biosciences Inc. in the live analysis

One click puts Neurocrine Biosciences Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.